Using a blood test to track EBV in NK/T cell lymphoma
Part of Blood & lymphatic, Cancer, Infections clinical trials.
This study looks at whether a specific blood test (free methylated EBV DNA) can help track extranodal NK/T cell lymphoma and support care decisions. It is for people newly diagnosed, confirmed by tissue testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a new diagnosis of extranodal NK/T cell lymphoma
- Diagnosis must be confirmed by pathology (tissue) testing
- You must be able to sign informed consent
- You must be able to attend study visits and follow study procedures
- There must not be other major health factors that could affect safety or results
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects medical information and blood samples from people with Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases to better understand how these conditions progress and respond to treatment. It includes a retrospective part (looking back at medical records) and a prospective part (following people forward in time).
This trial tests a new cell therapy (TCR-T cells) for people with EBV-positive lymphoma that has not responded to standard treatments or has come back. The therapy uses your own immune cells that have been specially trained to find and attack cancer cells carrying the EBV virus.
This trial uses PET scans and EBV DNA levels to personalize treatment for patients with early-stage nasal NK/T cell lymphoma. It aims to reduce side effects by adjusting therapy based on how well the cancer responds.
This study checks whether measuring a blood test called “circulating tumor DNA” (ctDNA) helps monitor childhood lymphoma during treatment. It’s meant to see if ctDNA tracking can provide useful information alongside standard exams.
This trial checks whether a blood test that looks for cancer DNA can help guide and monitor treatment in people with advanced non-small cell lung cancer (NSCLC). It may help your team spot treatment response or changes earlier, so care can be adjusted appropriately.
This trial studies whether tracking levels of Epstein-Barr virus DNA in your blood can help guide treatment for non-metastatic nasopharyngeal cancer. You would get standard radiation and maybe chemotherapy, with extra blood tests to see how the virus levels change.
Hear when a new Extranodal Natural Killer T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.